ES3049513T3 - Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation - Google Patents

Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Info

Publication number
ES3049513T3
ES3049513T3 ES19710488T ES19710488T ES3049513T3 ES 3049513 T3 ES3049513 T3 ES 3049513T3 ES 19710488 T ES19710488 T ES 19710488T ES 19710488 T ES19710488 T ES 19710488T ES 3049513 T3 ES3049513 T3 ES 3049513T3
Authority
ES
Spain
Prior art keywords
approximately
nemolizumab
excoriations
weeks
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19710488T
Other languages
English (en)
Spanish (es)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65729402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3049513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Application granted granted Critical
Publication of ES3049513T3 publication Critical patent/ES3049513T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES19710488T 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation Active ES3049513T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
ES3049513T3 true ES3049513T3 (en) 2025-12-17

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19710488T Active ES3049513T3 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Country Status (23)

Country Link
US (2) US12435147B2 (cg-RX-API-DMAC7.html)
EP (2) EP4644424A3 (cg-RX-API-DMAC7.html)
JP (3) JP7777921B2 (cg-RX-API-DMAC7.html)
CN (1) CN112040976A (cg-RX-API-DMAC7.html)
AU (2) AU2019219608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016144A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002050A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749353T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049513T3 (cg-RX-API-DMAC7.html)
FI (1) FI3749353T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251101T1 (cg-RX-API-DMAC7.html)
IL (1) IL276524A (cg-RX-API-DMAC7.html)
LT (1) LT3749353T (cg-RX-API-DMAC7.html)
MX (1) MX2020008193A (cg-RX-API-DMAC7.html)
PH (1) PH12020551185A1 (cg-RX-API-DMAC7.html)
PL (1) PL3749353T3 (cg-RX-API-DMAC7.html)
PT (1) PT3749353T (cg-RX-API-DMAC7.html)
RU (1) RU2758378C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007558YA (cg-RX-API-DMAC7.html)
SI (1) SI3749353T1 (cg-RX-API-DMAC7.html)
TW (2) TWI856006B (cg-RX-API-DMAC7.html)
WO (1) WO2019155427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
IL276524A (en) 2020-09-30
JP2023182632A (ja) 2023-12-26
EP4644424A3 (en) 2026-01-14
TW202448919A (zh) 2024-12-16
WO2019155427A1 (en) 2019-08-15
CL2020002050A1 (es) 2020-12-11
RU2758378C1 (ru) 2021-10-28
CA3090062A1 (en) 2019-08-15
TWI856006B (zh) 2024-09-21
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
PH12020551185A1 (en) 2021-05-17
HRP20251101T1 (hr) 2025-11-21
JP7777921B2 (ja) 2025-12-01
US20200385476A1 (en) 2020-12-10
SI3749353T1 (sl) 2025-10-30
EP3749353B1 (en) 2025-07-30
TWI923998B (zh) 2026-05-01
JP2025176134A (ja) 2025-12-03
AU2019219608B2 (en) 2025-10-16
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
EP4644424A2 (en) 2025-11-05
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
TW201941800A (zh) 2019-11-01
JP2021512917A (ja) 2021-05-20
US20260008859A1 (en) 2026-01-08
SG11202007558YA (en) 2020-09-29
PL3749353T3 (pl) 2025-12-08
DK3749353T3 (da) 2025-09-01
FI3749353T3 (fi) 2025-09-10
BR112020016144A2 (pt) 2020-12-15
PT3749353T (pt) 2025-10-14
CN112040976A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
US20200031937A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
RU2749512C2 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20230391878A1 (en) Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
CA3228708A1 (en) Treatment of atopic dermatitis
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
ES2572368T5 (es) Tratamiento de la artrosis
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
CA3257386A1 (en) METHOD FOR TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
US20250066467A1 (en) Methods for the treatment of myasthenia gravis